| Name | Title | Contact Details |
|---|---|---|
Pat Higgins |
Senior Director, Global Alliance Management & Commercial Counsel | Profile |
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
We`re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we`re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We`re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.
Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients.
Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.
Verax Biomedical Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.